for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Integra Lifesciences Holdings Corp

IART.OQ

Latest Trade

60.65USD

Change

-0.41(-0.67%)

Volume

2,533

Today's Range

60.65

 - 

60.65

52 Week Range

42.17

 - 

66.41

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
61.06
Open
60.65
Volume
2,533
3M AVG Volume
9.77
Today's High
60.65
Today's Low
60.65
52 Week High
66.41
52 Week Low
42.17
Shares Out (MIL)
85.53
Market Cap (MIL)
5,222.73
Forward P/E
22.33
Dividend (Yield %)
--

Next Event

Q3 2019 Integra Lifesciences Holdings Corp Earnings Release

Latest Developments

More

Integra Lifesciences Reports Second Quarter GAAP Earnings Per Share Of $0.34

Integra Lifesciences Announces Appointment Of Carrie Anderson As CFO

Integra Lifesciences Holdings Corp Says Unit Received A Warning Letter, Dated March 6 From U.S. FDA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Integra Lifesciences Holdings Corp

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

Industry

Scientific & Technical Instr.

Contact Info

311 Enterprise Dr

+1.609.2750500

https://www.integralife.com/

Executive Leadership

Stuart M. Essig

Independent Chairman of the Board

Peter J. Arduini

President, Chief Executive Officer, Director

Carrie L. Anderson

Chief Financial Officer and Principal Financial Officer, Corporate Vice President

Glenn G. Coleman

Chief Operating Officer, Corporate Vice President

Lisa Evoli

Corporate Vice President, Chief Human Resources Officer

Key Stats

2.29 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.0K

2017

1.2K

2018

1.5K

2019(E)

1.5K
EPS (USD)

2016

1.760

2017

1.940

2018

2.420

2019(E)

2.734
Price To Earnings (TTM)
52.24
Price To Sales (TTM)
3.50
Price To Book (MRQ)
3.67
Price To Cash Flow (TTM)
24.12
Total Debt To Equity (MRQ)
95.14
LT Debt To Equity (MRQ)
91.98
Return on Investment (TTM)
3.41
Return on Equity (TTM)
3.12

Latest News

Integra gets FDA warning letter for Boston plant

Medical device maker Integra Lifesciences Holdings Corp said on Monday it had received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in Boston.

Integra gets FDA warning letter for Boston plant

Medical device maker Integra Lifesciences Holdings Corp said on Monday it had received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in Boston.

BRIEF-Integra Lifesciences Prices Public Offering Of Common Stock

* INTEGRA LIFESCIENCES PRICES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Integra LifeSciences Announces Proposed Public Offering Of Common Stock

* INTEGRA LIFESCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Integra Lifesciences Announces Amendment And Extension Of Credit Facility

* INTEGRA LIFESCIENCES ANNOUNCES AMENDMENT AND EXTENSION OF CREDIT FACILITY

BRIEF-Integra Lifesciences Reports Q1 Adjusted Earnings Per Share $0.58

* INTEGRA LIFESCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Integra LifeSciences Says CEO's 2017 Compensation Was $7.1 Mln

* INTEGRA LIFESCIENCES HOLDINGS CORP SAYS CEO PETER J. ARDUINI'S 2017 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $7 MILLION IN 2016 – SEC FILING Source: (https://bit.ly/2HdNFnd) Further company coverage:

BRIEF-Integra Lifesciences Holdings Reports Q4 EPS Of $0.56

* INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Integra Lifesciences Q4 Adjusted Earnings Per Share $0.64

* INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Integra Lifesciences Announces Preliminary Q4 Earnings Per Share View $0.55, Revenue View $351.0

* - ORGANIC REVENUE GROWTH IN Q4 IS EXPECTED TO BE ABOUT 5.5%, ABOVE COMPANY'S IMPLIED GUIDANCE OF ABOUT 4%

BRIEF-Capital Research Global Investors Reports 11.1 Pct Passive Stake In Integra Lifesciences As Of Nov 30

* CAPITAL RESEARCH GLOBAL INVESTORS REPORTS 11.1 PERCENT PASSIVE STAKE IN INTEGRA LIFESCIENCES HOLDINGS CORP AS OF NOVEMBER 30 - SEC FILING Source text: (http://bit.ly/2jb88l1) Further company coverage:

BRIEF-Integra Lifesciences Q3 adjusted earnings per share $0.45

* Integra Lifesciences reports third quarter 2017 financial results

BRIEF-JNJ announces completion of Codman Neurosurgery divestiture to Integra Lifesciences

* Johnson & Johnson announces completion of Codman Neurosurgery divestiture to Integra Lifesciences Holding Corporation Source text for Eikon: Further company coverage:

FTC approves Integra purchase of J&J’s Codman business

Medical device maker Integra LifeSciences Holdings Corp has received U.S. antitrust approval to buy Johnson & Johnson's Codman Neuro Division, the Federal Trade Commission said on Wednesday.

FTC allows Integra to buy J&J’s Codman neuro business, with conditions

Medical device maker Integra LifeSciences Holdings Corp has received U.S. antitrust approval to buy Johnson & Johnson's Codman Neuro Division, the Federal Trade Commission said on Wednesday.

BRIEF-Integra lifesciences reports preliminary assessment of damage to Puerto Rico facility

* Integra Lifesciences provides preliminary assessment of minor damage to its manufacturing facility in Añasco, Puerto Rico

BRIEF-Integra LifeSciences announces first patient enrolled in Cadence® total ankle system post-market study

* Integra LifeSciences announces first patient enrolled in Cadence® total ankle system post-market study Source text for Eikon: Further company coverage:

BRIEF-Natus to acquire neurosurgery assets from Integra Lifesciences

* Natus to acquire neurosurgery assets from Integra Lifesciences, enters neurosurgery market

BRIEF-Integra Lifesciences to sell neurosurgery assets to Natus Medical

* Integra Lifesciences announces definitive agreement to sell certain neurosurgery assets to Natus Medical Incorporated

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up